[1] Liu H, Wang X, Liu L, et al. Targeting liposarcoma: unveiling molecular pathways and therapeutic opportunities[J/OL]. Front Oncol, 2024, doi:10.3389/fonc.2024.1484027. [2] Kyriazoglou A, Pagkali A, Kotsantis I, et al. Well-differentiated liposarcomas and dedifferentiated liposarcomas: systemic treatment options for two sibling neoplasms[J/OL]. Cancer Treat Rev, 2024, 125: 102716. doi:10.1016/j.ctrv.2024.102716. [3] Thway K, Jones RL, Noujaim J, et al. Dedifferentiated liposarcoma: updates on morphology, genetics, and therapeutic strategies[J/OL]. Adv in Anat Pathol, 2016, 23: 30-40. doi:10.1097/PAP.0000000000000101. [4] Lee ATJ, Thway K, Huang PH, et al. Clinical and molecular spectrum of liposarcoma[J/OL]. J Clin Oncol, 2018, 36: 151-159. doi:10.1200/JCO.2017.74.9598. [5] Seung SJ, Wong A, Milan R, et al. Epidemiology, treatment patterns, survival, healthcare resource utilization, and costs of dedifferentiated liposarcoma (DDLPS) in Canada: a retrospective cohort study using administrative databases in Ontario[J/OL]. Curr Oncol, 2025, 32: 273. doi:10.3390/curroncol32050273. [6] Francis IR. Retroperitoneal sarcomas[J/OL]. Cancer Imaging, 2005, 5: 89-94. doi:10.1102/1470-7330.2005.0019. [7] Masroori Z, Mirghaderi P, Haseli S, et al. Pictorial review of soft tissue lesions with calcification[J/OL]. Diagnostics, 2025, 15: 811. doi:10.3390/diagnostics15070811. [8] De Sanctis R, Giordano L, Colombo C, et al. Long-term follow-up and post-relapse outcome of patients with localized retroperitoneal sarcoma treated in the Italian sarcoma group-soft tissue sarcoma (ISG-STS) protocol 0303[J/OL]. Ann Surg Oncol, 2017, 24: 3872-3879. doi:10.1245/s10434-017-6105-y. [9] Jolissaint JS, Raut CP, Fairweather M. Management of recurrent retroperitoneal sarcoma[J/OL]. Curr Oncol, 2023, 30: 2761-2769. doi:10.3390/curroncol30030209. [10] Haddox CL, Nathenson MJ, Mazzola E, et al. Phase Ⅱ study of eribulin plus pembrolizumab in metastatic soft-tissue sarcomas: clinical outcomes and biological correlates[J/OL]. Clin Cancer Res, 2024, 30: 1281-1292. doi:10.1158/1078-0432.CCR-23-2250. [11] Haddox CL, Hornick JL, Roland CL, et al. Diagnosis and management of dedifferentiated liposarcoma: a multidisciplinary position statement[J/OL]. Cancer Treat Rev, 2024, 131: 102846. doi:10.1016/j.ctrv.2024.102846. |